Tellgen Corporation's Subsidiaries Obtain Regulatory Approvals for Two Diagnostic Products

Stock News

2 hours ago

Tellgen Corporation (300642.SZ) has officially announced that its controlling subsidiaries, Jiangxi Tellgen Life Science Technology Co., Ltd. and Shanghai Maishi Biotechnology Co., Ltd., have recently secured medical device registration certificates from the Jiangxi Medical Products Administration and the Shanghai Medical Products Administration, respectively.

The newly approved products include the fully automated flow fluorescence luminescence immunoassay analyzer, available in models TESMIF5000 and TESMIF5000M, as well as a four-item anti-epileptic drug concentration assay kit utilizing liquid chromatography-tandem mass spectrometry methodology.

These regulatory clearances mark a significant milestone for the company's subsidiaries, expanding their product portfolios in the in-vitro diagnostics sector and reinforcing their market presence across the region.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1157650345"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1157650345\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1157650345?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-18 19:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157650345","market":"sh","top_or_hot":-1,"title":"Tellgen Corporation's Subsidiaries Obtain Regulatory Approvals for Two Diagnostic Products","media":"Stock News","content":"<p><b>Tellgen Corporation</b> (300642.SZ) has officially announced that its controlling subsidiaries, Jiangxi Tellgen Life Science Technology Co., Ltd. and Shanghai Maishi Biotechnology Co., Ltd., have recently secured medical device registration certificates from the Jiangxi Medical Products Administration and the Shanghai Medical Products Administration, respectively.<br><br>The newly approved products include the fully automated flow fluorescence luminescence immunoassay analyzer, available in models TESMIF5000 and TESMIF5000M, as well as a four-item anti-epileptic drug concentration assay kit utilizing liquid chromatography-tandem mass spectrometry methodology.<br><br>These regulatory clearances mark a significant milestone for the company's subsidiaries, expanding their product portfolios in the in-vitro diagnostics sector and reinforcing their market presence across the region.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tellgen Corporation's Subsidiaries Obtain Regulatory Approvals for Two Diagnostic Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTellgen Corporation's Subsidiaries Obtain Regulatory Approvals for Two Diagnostic Products\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-18 19:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Tellgen Corporation</b> (300642.SZ) has officially announced that its controlling subsidiaries, Jiangxi Tellgen Life Science Technology Co., Ltd. and Shanghai Maishi Biotechnology Co., Ltd., have recently secured medical device registration certificates from the Jiangxi Medical Products Administration and the Shanghai Medical Products Administration, respectively.<br><br>The newly approved products include the fully automated flow fluorescence luminescence immunoassay analyzer, available in models TESMIF5000 and TESMIF5000M, as well as a four-item anti-epileptic drug concentration assay kit utilizing liquid chromatography-tandem mass spectrometry methodology.<br><br>These regulatory clearances mark a significant milestone for the company's subsidiaries, expanding their product portfolios in the in-vitro diagnostics sector and reinforcing their market presence across the region.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0046","symbol_name":"生物疫苗","start_time":0,"source_url":"","article_id":"1157650345","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157650345","pubTimestamp":1789732702,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Tellgen Corporation (300642.SZ) has officially announced that its controlling subsidiaries, Jiangxi Tellgen Life Science Technology Co., Ltd. and Shanghai Maishi Biotechnology Co., Ltd., have...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159883":"医疗器械","300642":"透景生命","BK0046":"生物疫苗","LNGR":"Global X Longevity Thematic ETF","RSPH":"Invesco S&P 500 Equal Weight Health Care ETF","GDOC":"Goldman Sachs Future Health Care Equity ETF","PTH":"Invesco Dorsey Wright Healthcare Momentum ETF","09996":"沛嘉医疗-B","IEIH":"iShares Evolved U.S. Innovative Healthcare ETF","BK0042":"基因检测","MDEV":"First Trust Indxx Medical Devices ETF","HART":"NYLI Healthy Hearts ETF","BK1100":"医疗保健设备","MEDX":"HORIZON KINETICS MEDICAL ETF","LGHT":"LANGAR GLOBAL HEALTHTECH ETF","BK1574":"生物医药B类股","AGNG":"Global X Aging Population ETF","BK1583":"高瓴概念","BK0239":"医药制造"},"translate_title":"Tellgen Corporation 子公司获得两种诊断产品的监管部门批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159883":1,"300642":1,"LNGR":1,"09996":1,"IEIH":1,"MEDX":1,"LGHT":1,"MDEV":1,"HART":1,"RSPH":1,"PTH":1,"GDOC":1,"AGNG":1},"content_text":"Tellgen Corporation (300642.SZ) has officially announced that its controlling subsidiaries, Jiangxi Tellgen Life Science Technology Co., Ltd. and Shanghai Maishi Biotechnology Co., Ltd., have recently secured medical device registration certificates from the Jiangxi Medical Products Administration and the Shanghai Medical Products Administration, respectively.The newly approved products include the fully automated flow fluorescence luminescence immunoassay analyzer, available in models TESMIF5000 and TESMIF5000M, as well as a four-item anti-epileptic drug concentration assay kit utilizing liquid chromatography-tandem mass spectrometry methodology.These regulatory clearances mark a significant milestone for the company's subsidiaries, expanding their product portfolios in the in-vitro diagnostics sector and reinforcing their market presence across the region.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}